

272

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
TRANSMITTAL FORM

In re Application of  
LANAR et al.

Serial No.: 10/706,435

Filed: November 12, 2003

For: Expression, Purification and Uses of a *Plasmodium falciparum* Liver Stage Antigen  
1 Polypeptide

Examiner: Unknown

Group Art Unit :

Attny Docket: 003/285/SAP

\*\*\*\*\*

11 January 2005

Mail Stop: Non-Fee Amendment  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

Transmitted for filing herewith are the following items:

☒ Information Disclosure Statement

☒ 1449 form

Fee required \$0.00

Please charge the above fee and any missing or inadequate fee re this paper to  
Deposit Account No. **21-0380** for which purpose a duplicate copy of this sheet is  
attached.

Respectfully submitted,


by Elizabeth Arwine Reg No. 39,441  
for Elizabeth Arwine  
U.S. Agent No. 45,867

U.S. Army Medical and Materiel Command  
504 Scott Street  
Fort Detrick, Maryland 21702-5012  
ATTN: MCMR JA (Elizabeth Arwine- Patent Atty)

I hereby certify that this correspondence is being deposited with the United States  
Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail  
Stop: Non-Fee Amendment, P. O. Box 1450, Alexandria, VA 22313-1450 on the date of  
11 January 2005.

Respectfully submitted,

by Sana A. Pratt  
Sana A. Pratt



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

LANAR et al.

Serial No.: 10/706,435

Filed: November 12, 2003

For: Expression, Purification and Uses of a *Plasmodium falciparum* Liver Stage Antigen  
1 Polypeptide

Examiner: Unknown

Group Art Unit : Unknown

Attny Docket: 003/285/SAP

\*\*\*\*\*

11 January 2005

**INFORMATION DISCLOSURE STATEMENT**

Mail Stop Non-Fee Amendment  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In connection with the subject application, submitted herewith is a PTO form 1449 disclosing one reference, a U.S. Patent disclosing peptide sequences for liver stage antigens of *P. falciparum* .

This IDS is intended to be in full compliance with the rules but should the Examiner find any part of the requirements to have been omitted, prompt notice to that effect is requested along with additional time under Rule 97(f) to enable applicants to comply.

Lanar et al., 10/706,435  
11 January 2005

Consideration of the foregoing and enclosures plus the return of a copy of the herewith Form PTO-1449 with Examiner's initials in the left column per MPEP 609 are earnestly solicited.

Respectfully submitted,

By *S. Pratt* Reg No. 39,441  
for Elizabeth Arwine  
U.S. Reg. No. 45,867

U.S. A. MPMC  
504 Scott Street  
Fort Detrick, MD 21702-5012  
ATTN: MCMR -JA (Elizabeth Arwine-Patent Atty)

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Mail Stop: Non Fee Amendment, P. O. Box 1450, Alexandria, VA 22313-1450 on 11 January 2005.

By *S. Pratt*  
Sana A. Pratt  
U.S. Reg. No. 39,441

DATE: 11 January 2005

Sheet 1 of 1

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

GROUP ART UNIT: Unknown

CLIENT /MATTER: 003/285/SAP

APPLICANT (inventors)  
Lanar et al.

EXAMINER  
Unknown

APPLICATION NO.  
10/706,435

FILING DATE  
November 12, 2003

**U. S. PATENT DOCUMENTS**

Examiner's Initials	Document Number	Date Mo./Yr.	Name (Family Name of First Inventor)	Class	Subclass	Filing Date If appropriate
AR	6 3 1 9 5 0 2	11/01	Guerin-Marchand et al.			
BR						
CR						
DR						
ER						
FR						
GR						

**FOREIGN PATENT DOCUMENTS**

	Document Number	Date Mo./Yr.	Country	English Abstract		Class	Subclass	Translation Available	
				Enclosed	No			Enclosed	No
NR									

**OTHER DOCUMENTS** (Including in this order, Author, Title, Periodical Name, Date, Pertinent Pages, Etc.)

QR	
RR	
SR	
TR	
UR	
VR	
WR	

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.